Trial Profile

A Phase III trial of Elamipretide in Leber's hereditary optic neuropathy

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 20 Aug 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elamipretide (Primary)
Indications Leber's hereditary optic atrophy
Focus Registrational; Therapeutic Use
Sponsors Stealth BioTherapeutics

Most Recent Events

20 Aug 2019 New trial record
14 Aug 2019 According to a Stealth BioTherapeutics media release,the company has reached on an alignment with the Division of Ophthalmology Products at FDA regarding key aspects of this trial. The company plans to submit Phase 3 protocol to the FDA by year-end.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com